One of the bottlenecks in CAR-T therapeutic development is evaluating the biofunction of effector cells. This in vitro process involves a series of labor-intensive co-culture immunoassays. To address this challenge, we generated luciferase reporter cell lines that have high endogenous expression of clinically relevant cell surface tumor antigens such as CD19, CD20, and HER2. These new immuno-oncology tools include both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression. These cells enable your immuno-therapeutic breakthroughs by allowing you to monitor the potency and efficacy of candidate CAR-T effector cells in your cytotoxicity and cell viability assays in real time.

Table 1: CAR-T Target Luciferase Reporter Cells

Designation	ATCC® No.	Disease	Target
WIL2-S-Luc2	CRL-8885-LUC2™	B Cell Lymphoma	CD19
Raji-Luc2	CCL-86-LUC2™	Burkitt’s Lymphoma	CD19
Daudi-Luc2	CCL-213-LUC2™	Burkitt’s Lymphoma	CD20
Farage-Luc2	CRL-2630-LUC2™	Non-Hodgkin’s B Cell Lymphoma	CD20
BT-474-Luc2	HTB-20-LUC2™	Breast Ductal Carcinoma	HER2

We are offering 10% off Checkpoint and CAR-T Target Reporter Models* Use promo code ATCC-000028 at checkout to take advantage of this special discount. This limited-time offer is effective from April 1 - May 15, 2024, so place your order before time runs out! *Offer is effective from April 1st – May 15th, 2024. The 10% discount applies only to ATCC Checkpoint and CAR-T Target Reporter Models; all other items are excluded from this promotion. For non-profit customers, the promotional discount is applied to the customer-specific pricing. The promo code must be applied at the time of checkout. The promo code must be applied in the “Promotional code” field in the shopping cart. U.S. customers only. Void where prohibited. Restrictions may apply. Limit 20 vials.

These convenient reporter-labeled cells allow you to eliminate workflows involving radioactive or fluorescent dye labeling. The cells retain high expression of both the target antigen and luciferase up to 30 population doublings. These flexible target cells can also be incorporated in other immuno-oncology applications such as ADCC and natural killer (NK) cell cytotoxicity assays.

• High expression stability of both target antigen and luciferase
• High signal-to-noise ratio (S/N)
• Physiologically relevant low E:T ratios
• High-performing, fully authenticated cell lines
• Easy-to-use reporter system
• Real-time, live-cell imaging possible

 

CAR-T Effector Cell Efficacy Using Raji-Luc2 and WIL2-S-Luc2

CAR-T Target Luciferase Reporter Cells can be incorporated into multiple CAR-T efficacy assays. (A) CD19 expressing Raji-Luc2 cells (B) or WIL2-SLuc2 cells were used as target cells for either CD19 CAR-T or Mock CAR-T (control) effector cells from the same donor at the indicated effector to target cell ratios. A luciferase assay substrate was added, and the luminescence signal was detected. Loss of signal indicates cell death; the dose-dependent specific killing via CD19-targeting CAR-T cells was greater than the non-specific killing observed with the mock CAR-T cells. Additionally, Raji-Luc2 cells were stained with a cell labeling dye and then real-time fluorescent imaging was measured during co-culture with CD19 CAR-T effector cells. (C) Raji-Luc2 cells (Green) are surrounded by effector T cells, resulting in a decrease of fluorescence as compared to co-cultures with Mock-CAR-T cells. (D) After 6 and 24 hours of co-culture with CD19 CAR-T effector cells, we observed a decrease in the number of fluorescent cells; however, in a co-culture with Mock CAR-T cells numerous Raji-LUC2 cells were present. These results indicate that the ATCC CAR-T Target Luciferase Reporter Cells can be used to evaluate the potency of CAR-T cells in bioluminescence assays and live cell imaging in real time.